EBV-BZLF1 Promotes Gastric Cancer Growth Through Activating the PI3K/AKT Pathway

B. Li,M. Zhang,C. Zhang,L. Shen,Jing Gao
DOI: https://doi.org/10.1200/JGO.18.88100
2018-09-28
Journal of Global Oncology
Abstract:Background: EBVaGC (EBV associated gastric cancer) had been paid much attentions once classified by TCGA and were considered as the suitable group for immunotherapy, which hold distinguishing characteristics with EBVnGC (EBV nonassociated gastric cancer). This study aims to explore the biologic behavior and its possible mechanisms to provide treatment options for EBVaGC. Methods: Lentiviral infection system was used to construct the control and BZLF1 stably expressing gastric cancer cell lines (AGS and HGC27). The cell-derived xenografts (CDX) were constructed to detect the tumor growth and functional experiment including CCK8 assay, cell cycle assay, apoptosis assay, cell migration and invasion assay were implemented to detect the proliferation and transfer ability in vitro. Western blot and immunohistochemistry were used to detect the expression of related molecules. Results: The BZLF1 overexpression cells and the corresponding xenografts grew faster than control groups with enhanced pAKT and pS6 expression. BZLF1 induced “G0/1 phase” arrest in AGS and “S phase” arrest in HGC27 cell, inhibited cell apoptosis through upregulating bcl-2 protein, meanwhile, slightly increased P53 and p-P53 expression in both BZLF1 overexpression cells. However, no significant effects were observed on the malignant biologic behaviors in terms of migration and invasion ability. Conclusion: BZLF1 may promote the growth of gastric cancer through activating the PI3K/AKT pathway, regulating the cell cycle especially regarding P53 signaling network. PI3K/AKT pathway inhibitor probably become promising treatment options for EBVaGC.
Medicine
What problem does this paper attempt to address?